Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Small Molecule Inhibitors as a Novel Therapy for Atherosclerosis

EF 2023-24

Résumé
Atherosclerosis, heart disease, and stroke remain the leading causes of death worldwide, with atherosclerosis effecting more than half of the population over the age of 50. Current therapies for atherosclerosis focus on reducing blood lipid levels to reduce the development of and improve plaque stability. Statins and monoclonal antibody therapies, while undeniably effective, fail to address the inflammatory response associated with atherosclerosis. Emerging research develops implicates atherosclerosis as an immunological disorder of the cardiovascular system and not just a lipid disorder. Inflammation associated with atherosclerosis has also been implicated as causative for the most serious complications including thrombosis, stroke, and myocardial infarction. Despite the understood role of inflammation in atherogenesis and cardiovascular disease, anti-inflammatory therapies for atherosclerosis remain limited. Here we propose the use of a small molecule inhibitor GSK2636771, which has previously been described as protective against transplant vasculopathy, vascular inflammation resulting from transplant rejection, as a novel therapy for reducing inflammation in atherosclerosis. We intend to use a murine model with a traditional and well described high-fat high-cholesterol diet, to induce atherogenesis and explore the vascular protective effects of the small molecule in this new context.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506368
Name
Ness Nathan W
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Small Molecule Inhibitors as a Novel Therapy for Atherosclerosis
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atherosclerosis; Cardiovascular; Cholesterol; Heart Disease; Hypertension; Inflammation; Lipids; Plaque; Stroke; Thrombosis
Abstract
Atherosclerosis, heart disease, and stroke remain the leading causes of death worldwide, with atherosclerosis effecting more than half of the population over the age of 50. Current therapies for atherosclerosis focus on reducing blood lipid levels to reduce the development of and improve plaque stability. Statins and monoclonal antibody therapies, while undeniably effective, fail to address the inflammatory response associated with atherosclerosis. Emerging research develops implicates atherosclerosis as an immunological disorder of the cardiovascular system and not just a lipid disorder. Inflammation associated with atherosclerosis has also been implicated as causative for the most serious complications including thrombosis, stroke, and myocardial infarction. Despite the understood role of inflammation in atherogenesis and cardiovascular disease, anti-inflammatory therapies for atherosclerosis remain limited. Here we propose the use of a small molecule inhibitor GSK2636771, which has previously been described as protective against transplant vasculopathy, vascular inflammation resulting from transplant rejection, as a novel therapy for reducing inflammation in atherosclerosis. We intend to use a murine model with a traditional and well described high-fat high-cholesterol diet, to induce atherogenesis and explore the vascular protective effects of the small molecule in this new context.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ness, Nathan W
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~